Literature DB >> 8856684

Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo.

T E Bates1, M Strangward, J Keelan, G P Davey, P M Munro, J B Clark.   

Abstract

The effect of specific irreversible inhibitors of complexes I, III, IV and V of the mitochondrial respiratory chain, (rotenone, myxothiazol, cyanide and oligomycin, respectively) on mitochondrial N-acetylaspartate production, and its relationship to oxidative phosphorylation (ATP production and oxygen consumption) were investigated in isolated rat brain mitochondria. Mitochondrial N-acetylaspartate production, ATP production and oxygen consumption were all significantly decreased in the presence of each of the inhibitors used compared with control incubations, and correlated positively with each other. It is postulated that decreased N-acetylaspartate levels seen in disease states by 1H NMR spectroscopy in vivo may reflect primarily an impaired mitochondrial energy production rather than neuronal cell loss.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8856684

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  142 in total

1.  Ketogenic diet prevents alterations in brain metabolism in young but not adult rats after traumatic brain injury.

Authors:  Ying Deng-Bryant; Mayumi L Prins; David A Hovda; Neil G Harris
Journal:  J Neurotrauma       Date:  2011-08-04       Impact factor: 5.269

2.  Whole-Brain N-Acetylaspartate Concentration Is Preserved during Mild Hypercapnia Challenge.

Authors:  S Chawla; Y Ge; H Lu; O Marshall; M S Davitz; G Fatterpekar; B J Soher; O Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2015-08-20       Impact factor: 3.825

3.  Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.

Authors:  Tatsunobu Natsubori; Hideyuki Inoue; Osamu Abe; Yosuke Takano; Norichika Iwashiro; Yuta Aoki; Shinsuke Koike; Noriaki Yahata; Masaki Katsura; Wataru Gonoi; Hiroki Sasaki; Hidemasa Takao; Kiyoto Kasai; Hidenori Yamasue
Journal:  Schizophr Bull       Date:  2013-09-10       Impact factor: 9.306

Review 4.  Review: Mitochondria and disease progression in multiple sclerosis.

Authors:  D Mahad; H Lassmann; D Turnbull
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12       Impact factor: 8.090

5.  Occipital cortical proton MRS at 4 Tesla in human moderate MDMA polydrug users.

Authors:  Ronald L Cowan; Nicolas R Bolo; Mary Dietrich; Erica Haga; Scott E Lukas; Perry F Renshaw
Journal:  Psychiatry Res       Date:  2007-06-18       Impact factor: 3.222

6.  Effect of cholinergic signaling on neuronal cell bioenergetics.

Authors:  Jianghua Lu; Lezi E; Nairita Roy; Lewis Hutfles; Eva Selfridge; Eric Funk; Jeffrey M Burns; Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  Transcriptional regulation of N-acetylaspartate metabolism in the 5xFAD model of Alzheimer's disease: evidence for neuron-glia communication during energetic crisis.

Authors:  Samantha Zaroff; Paola Leone; Vladimir Markov; Jeremy S Francis
Journal:  Mol Cell Neurosci       Date:  2015-03-10       Impact factor: 4.314

Review 8.  A review of MR spectroscopy studies of pediatric bipolar disorder.

Authors:  D G Kondo; T L Hellem; X-F Shi; Y H Sung; A P Prescot; T S Kim; R S Huber; L N Forrest; P F Renshaw
Journal:  AJNR Am J Neuroradiol       Date:  2014-02-20       Impact factor: 3.825

9.  Low docosahexaenoic acid status is associated with reduced indices in cortical integrity in the anterior cingulate of healthy male children: a 1H MRS Study.

Authors:  Robert K McNamara; Ronald Jandacek; Patrick Tso; Wade Weber; Wen-Jang Chu; Stephen M Strakowski; Caleb M Adler; Melissa P Delbello
Journal:  Nutr Neurosci       Date:  2013-07       Impact factor: 4.994

10.  Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington's disease.

Authors:  T M Tsang; J N Haselden; E Holmes
Journal:  Neurochem Res       Date:  2009-01-16       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.